We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ProMIS

News List

ProMIS Neurosciences Announces US$15 Million Offering of Units firstwordpharma
August 18, 2021
ProMIS has filed today a preliminary prospectus supplement (the "Supplement") to its final short form base shelf prospectus dated June 30, 2021 (the "Base Prospectus") in connection with a proposed commercially reasonable efforts public offering.
ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease americanpharmaceuticalreview
October 12, 2018
ProMIS Neurosciences announced the identification of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein α-synuclein, considered a root cause of Parkinson's disease (PD).
ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results biospace
March 15, 2018
ProMis Neurosciences, Inc., today announced its operational and financial results for the year ended December 31, 2017.
ProMIS Neurosciences Candidate for Alzheimer's Shows Potential for Improved Therapeutic Potency americanpharmaceuticalreview
January 24, 2018
ProMIS Neurosciences has announce its lead product candidate for AD, PMN310, compared to aducanumab showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta in brain extract from eight confirmed AD brains.